Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

by | Oct 29, 2026 | Clinical Trials | 0 comments

​ Conditions: Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: SYS6055

Sponsors: Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd

Not yet recruiting Conditions: Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Interventions: Drug: SYS6055
Sponsors: Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *